Selective HDAC3 inhibitors (e.g., RGFP966) also upregulated PD-L1 expression because HDAC3 was shown to repress PD-L1 transcription in B-cell lymphomas (Deng et al., 2019). Here, HDAC3 is linked to B-cell non-Hodgkin lymphoma.